The effect of cladribine on T1 'black hole' changes in progressive MS

M. Filippi, M. Rovaris, G. P A Rice, M. P. Sormani, G. Iannucci, L. Giacomotti, G. Comi

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We compared the changes of the volumes of T1-hypointense lesions seen on the magnetic resonance imaging scans of the brain from 159 progressive multiple sclerosis (MS) patients who were enrolled in a double-blind, placebo-controlled trial assessing the efficacy of two doses of cladribine. Although in patients treated with cladribine there was a tendency to have a lower increase of T1-hypointense lesion volumes than those treated with placebo, no statistically significant effect of cladribine on T1-hypointense lesion accumulation was found over the one-year double-blind phase. Furthermore, no significant treatment effect was also detected in a subset of 22 patients who received placebo during the double-blind phase of the study and cladribine during the subsequent one-year open-label phase. We conclude that cladribine does not have a major impact on the mechanisms leading to severe tissue destruction in progressive MS. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)42-44
Number of pages3
JournalJournal of the Neurological Sciences
Volume176
Issue number1
DOIs
Publication statusPublished - May 1 2000

Fingerprint

Cladribine
Multiple Sclerosis
Placebos
Double-Blind Method
Magnetic Resonance Imaging
Brain

Keywords

  • Cladribine
  • MRI
  • MS
  • T-hypointense lesions

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

The effect of cladribine on T1 'black hole' changes in progressive MS. / Filippi, M.; Rovaris, M.; Rice, G. P A; Sormani, M. P.; Iannucci, G.; Giacomotti, L.; Comi, G.

In: Journal of the Neurological Sciences, Vol. 176, No. 1, 01.05.2000, p. 42-44.

Research output: Contribution to journalArticle

Filippi, M. ; Rovaris, M. ; Rice, G. P A ; Sormani, M. P. ; Iannucci, G. ; Giacomotti, L. ; Comi, G. / The effect of cladribine on T1 'black hole' changes in progressive MS. In: Journal of the Neurological Sciences. 2000 ; Vol. 176, No. 1. pp. 42-44.
@article{e35b04febb1f4f46bb06f37e3f4784e8,
title = "The effect of cladribine on T1 'black hole' changes in progressive MS",
abstract = "We compared the changes of the volumes of T1-hypointense lesions seen on the magnetic resonance imaging scans of the brain from 159 progressive multiple sclerosis (MS) patients who were enrolled in a double-blind, placebo-controlled trial assessing the efficacy of two doses of cladribine. Although in patients treated with cladribine there was a tendency to have a lower increase of T1-hypointense lesion volumes than those treated with placebo, no statistically significant effect of cladribine on T1-hypointense lesion accumulation was found over the one-year double-blind phase. Furthermore, no significant treatment effect was also detected in a subset of 22 patients who received placebo during the double-blind phase of the study and cladribine during the subsequent one-year open-label phase. We conclude that cladribine does not have a major impact on the mechanisms leading to severe tissue destruction in progressive MS. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Cladribine, MRI, MS, T-hypointense lesions",
author = "M. Filippi and M. Rovaris and Rice, {G. P A} and Sormani, {M. P.} and G. Iannucci and L. Giacomotti and G. Comi",
year = "2000",
month = "5",
day = "1",
doi = "10.1016/S0022-510X(00)00303-8",
language = "English",
volume = "176",
pages = "42--44",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The effect of cladribine on T1 'black hole' changes in progressive MS

AU - Filippi, M.

AU - Rovaris, M.

AU - Rice, G. P A

AU - Sormani, M. P.

AU - Iannucci, G.

AU - Giacomotti, L.

AU - Comi, G.

PY - 2000/5/1

Y1 - 2000/5/1

N2 - We compared the changes of the volumes of T1-hypointense lesions seen on the magnetic resonance imaging scans of the brain from 159 progressive multiple sclerosis (MS) patients who were enrolled in a double-blind, placebo-controlled trial assessing the efficacy of two doses of cladribine. Although in patients treated with cladribine there was a tendency to have a lower increase of T1-hypointense lesion volumes than those treated with placebo, no statistically significant effect of cladribine on T1-hypointense lesion accumulation was found over the one-year double-blind phase. Furthermore, no significant treatment effect was also detected in a subset of 22 patients who received placebo during the double-blind phase of the study and cladribine during the subsequent one-year open-label phase. We conclude that cladribine does not have a major impact on the mechanisms leading to severe tissue destruction in progressive MS. Copyright (C) 2000 Elsevier Science B.V.

AB - We compared the changes of the volumes of T1-hypointense lesions seen on the magnetic resonance imaging scans of the brain from 159 progressive multiple sclerosis (MS) patients who were enrolled in a double-blind, placebo-controlled trial assessing the efficacy of two doses of cladribine. Although in patients treated with cladribine there was a tendency to have a lower increase of T1-hypointense lesion volumes than those treated with placebo, no statistically significant effect of cladribine on T1-hypointense lesion accumulation was found over the one-year double-blind phase. Furthermore, no significant treatment effect was also detected in a subset of 22 patients who received placebo during the double-blind phase of the study and cladribine during the subsequent one-year open-label phase. We conclude that cladribine does not have a major impact on the mechanisms leading to severe tissue destruction in progressive MS. Copyright (C) 2000 Elsevier Science B.V.

KW - Cladribine

KW - MRI

KW - MS

KW - T-hypointense lesions

UR - http://www.scopus.com/inward/record.url?scp=0034194016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034194016&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(00)00303-8

DO - 10.1016/S0022-510X(00)00303-8

M3 - Article

VL - 176

SP - 42

EP - 44

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1

ER -